TVTX- Travere Therapeutics, Inc.
TVTX sits in the Biotechnology industry within the Health Care sector, so this activity is best read against the sector's broader insider trend.
Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 432.9K | $26.07M | - | |
| Other | 138.6K | $8.35M | - | |
| Other | 123.1K | $7.41M | - | |
| CFO | 116.9K | $7.04M | - | |
| Other | 111.5K | $6.71M | - |
Activity
Buys and sells only
Transactions
10 filings · page 5
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 6, 2025 | Baynes Roy D. | Director | Sale+OE | 10,000 | $22.00 | $220,000.00 | -24.4% | -7.5% | +35.9% | |
| Feb 4, 2025 | Inrig Jula | Chief Medical Officer | Sell | 5,273 | $20.12 | $106,082.10 | -3.0% | +1.5% | +50.1% | |
| Feb 3, 2025 | Rote William E.58 | Senior Vice President, R&D | Sell | 8,951 | $19.78 | $177,050.78 | -8.6% | +5.9% | +62.4% | |
| Feb 3, 2025 | Reed Elizabeth E57 | SVP, GC &Corporate Secretary | Sell | 8,951 | $19.78 | $177,050.78 | -9.1% | +5.9% | +62.4% | |
| Feb 3, 2025 | Dube Eric M56 | Chief Executive Officer | Sell | 50,691 | $20.21 | $1,024,343.45 | -10.5% | +5.9% | +62.4% | |
| Feb 3, 2025 | Heerma Peter53 | Chief Commercial Officer | Sell | 5,166 | $20.12 | $103,939.92 | -4.0% | +5.9% | +62.4% | |
| Feb 3, 2025 | Cline Christopher R.48 | Chief Financial Officer | Sell | 5,192 | $20.12 | $104,463.04 | -5.5% | +5.9% | +62.4% | |
| Feb 3, 2025 | Calvin Sandra60 | SVP, Chief Accounting Officer | Sell | 3,348 | $20.12 | $67,361.76 | -5.0% | +5.9% | +62.4% | |
| Jan 23, 2025 | Baynes Roy D. | Director | Sale+OE | 16,000 | $20.00 | $320,000.00 | -34.0% | -19.8% | +41.5% | |
| Jan 22, 2025 | Rote William E.58 | Senior Vice President, R&D | Sell | 2,437 | $19.46 | $47,424.02 | -2.8% | -18.4% | +52.8% |